Bendamustine is the experimental drug of this trial, marketed by Mundipharma/Norpharma. The drug is approved in the participating countries for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma. It is a cytotoxic agent combining the 2-chlorethylamine group of the nitrogen mustard derived alkylating agents with the benzimidazole ring structures of the purine nucleoside analogues. Precautions and warnings include the possibility of myelosuppression, infections, skin reactions, caution in patients with cardiac disorders, nausea, vomiting, tumor lysis syndrome (very unlikely in primary CAD), anaphylaxis and extravasation.